Pomerantz Law Firm Notifies Investors of Action Against Capricor Therapeutics Amid Securities Fraud Allegations

Investor Alert: Class Action Lawsuit Against Capricor Therapeutics

Overview

Pomerantz Law Firm has recently alerted investors about a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR), focusing on alleged securities fraud and other illicit business practices. Affected investors are encouraged to take action before the deadline of September 28, 2026, if they purchased Capricor shares during the Class Period.

Background of the Lawsuit

The legal proceedings stem from the submission of Capricor’s Biologics License Application (BLA) for Deramiocel, intended as a cell therapy for Duchenne muscular dystrophy, to the U.S. Food and Drug Administration (FDA) in late 2024. However, in July 2025, Capricor received a Complete Response Letter from the FDA, which indicated that the application did not meet the necessary statutory requirements due to a lack of substantial evidence demonstrating effectiveness and the need for further clinical data.

Having stated that it addressed these issues by March 2026, Capricor faced further scrutiny just months later when the FDA disclosed critical briefing documents regarding the BLA ahead of an advisory committee meeting set for July 29, 2026. The briefing highlighted discrepancies in Capricor’s submission, particularly concerning the pre-specified statistical analysis plan (SAP) that was altered and submitted only one day before the data was unblinded. The FDA expressed concerns that this approach diminished the reliability of the findings.

On July 27, 2026, following the release of these documents, Capricor’s stock plummeted by $12.70 per share, a staggering 64% decline, closing the day at $7 per share. The ensuing advisory committee meeting raised more doubts about the efficacy of Deramiocel, leading to a further drop of $2.38 per share, bringing the price down to $4.19 per share by July 30, 2026.

Legal Representation

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class litigation, is leading this class action effort. Founded by Abraham L. Pomerantz, the firm specializes in advocating for investors' rights and recovering damages related to securities fraud and corporate misconduct. Interested investors may contact Danielle Peyton at Pomerantz by reaching out via email at [email protected] or by calling 646-581-9980.

Conclusion

As the deadline approaches, investors of Capricor Therapeutics who believe they have suffered losses due to the alleged misconduct are strongly encouraged to act swiftly. A link to the official complaint and further information on joining the class action can be found at Pomerantz Law Firm.

This class action represents a significant opportunity for investors impacted by the recent turbulence surrounding Capricor Therapeutics to seek justice and potentially recover losses incurred via their investments. With the legal landscape continuing to evolve, staying informed and proactive is essential.

Further Information

For more details regarding the class action and the steps to take to ensure eligibility to participate, investors may refer to the official website or contact Pomerantz LLP directly for personalized assistance.